[Research Progress on the Prognostic Evaluation of MRD in Acute Myeloid Leukemia --Review]

Acute myeloid leukemia (AML) is a highly heterogeneous group of malignant tumors in the blood system. Although many AML patients have achieved survive for a long time through chemotherapy and targeted therapy combined with/without HSCT, but some of them still be difficult to achieve remission or early relapse after remission. Therefore, refining risk stratification and achieving individualized treatment based on prognostic indicators is of great significance. As the research on prognostic indicators of AML deepens increasingly, the prognostic stratification has been continuously improved, from the MICM typing index to the comprehensive evaluation of biological disease characteristics such as MRD. This article reviews the development of prognostic indicators for AML and the research progress of MRD on AML prognosis evaluation to better identify patients with different risks and formulate and implement accurate diagnosis and treatment programs.